These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719 [TBL] [Abstract][Full Text] [Related]
6. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia. Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222 [TBL] [Abstract][Full Text] [Related]
7. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Jungbluth H; Lillis S; Zhou H; Abbs S; Sewry C; Swash M; Muntoni F Neuromuscul Disord; 2009 May; 19(5):344-7. PubMed ID: 19303294 [TBL] [Abstract][Full Text] [Related]
8. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility. Taylor A; Lachlan K; Manners RM; Lotery AJ J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266 [TBL] [Abstract][Full Text] [Related]
9. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084 [TBL] [Abstract][Full Text] [Related]
10. Mutations in RYR1 in malignant hyperthermia and central core disease. Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943 [TBL] [Abstract][Full Text] [Related]
11. Reduced threshold for store overload-induced Ca Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594 [TBL] [Abstract][Full Text] [Related]
12. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775 [TBL] [Abstract][Full Text] [Related]
13. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel. Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648 [TBL] [Abstract][Full Text] [Related]
14. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations. Knuiman GJ; Küsters B; Eshuis L; Snoeck M; Lammens M; Heytens L; De Ridder W; Baets J; Scalco RS; Quinlivan R; Holton J; Bodi I; Wraige E; Radunovic A; von Landenberg C; Reimann J; Kamsteeg EJ; Sewry C; Jungbluth H; Voermans NC J Neurol; 2019 Apr; 266(4):876-887. PubMed ID: 30788618 [TBL] [Abstract][Full Text] [Related]
15. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814 [TBL] [Abstract][Full Text] [Related]
16. Ryanodine receptor mutations in malignant hyperthermia and central core disease. McCarthy TV; Quane KA; Lynch PJ Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202 [TBL] [Abstract][Full Text] [Related]